bimagrumab + semaglutide

Bimagrumab + semaglutide is an **investigational combination therapy** pairing bimagrumab, a monoclonal antibody targeting activin type II receptors, with semaglutide, a glucagon-like peptide 1 receptor (GLP-1) agonist. **Bimagrumab** acts by blocking activin/myostatin signaling, thereby promoting skeletal muscle growth and preservation while reducing fat mass. **Semaglutide** reduces appetite and caloric intake by activating the GLP-1 receptor, leading to significant weight loss, primarily through the reduction of fat and some lean mass. Combined, these agents provide additive benefits in **fat mass reduction and muscle mass preservation**, resulting in greater weight loss with a higher proportion from fat and improved physical function compared to either monotherapy. The primary development focus is for **obesity and overweight**, addressing the challenge of lean mass loss during pharmacologic weight reduction. The combination therapy was evaluated in the phase 2b BELIEVE trial[1][2][3][4][7][9][10].